{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:39:45Z","timestamp":1792438785575,"version":"4.5.0"},"reference-count":191,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, accounting for 20% of osteoporosis diagnoses. Using glucocorticoids for &gt;6 months leads to osteoporosis in 50% of patients, resulting in an increased risk of fracture and death. Osteoblasts, osteocytes, and osteoclasts work together to maintain bone homeostasis. When bone formation and resorption are out of balance, abnormalities in bone structure or function may occur. Excess glucocorticoids disrupt the bone homeostasis by promoting osteoclast formation and prolonging osteoclasts' lifespan, leading to an increase in bone resorption. On the other hand, glucocorticoids inhibit osteoblasts' formation and facilitate apoptosis of osteoblasts and osteocytes, resulting in a reduction of bone formation. Several signaling pathways, signaling modulators, endocrines, and cytokines are involved in the molecular etiology of GIOP. Clinically, adults \u226540 years of age using glucocorticoids chronically with a high fracture risk are considered to have medical intervention. In addition to vitamin D and calcium tablet supplementations, the major therapeutic options approved for GIOP treatment include antiresorption drug bisphosphonates, parathyroid hormone N-terminal fragment teriparatide, and the monoclonal antibody denosumab. The selective estrogen receptor modulator can only be used under specific condition for postmenopausal women who have GIOP but fail to the regular GIOP treatment or have specific therapeutic contraindications. In this review, we focus on the molecular etiology of GIOP and the molecular pharmacology of the therapeutic drugs used for GIOP treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_233_20","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T16:42:13Z","timestamp":1617208933000},"page":"212-223","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":38,"title":["The molecular etiology and treatment of glucocorticoid-induced osteoporosis"],"prefix":"10.4103","volume":"33","author":[{"given":"Cheng-Huan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing-Ho","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Tien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Der","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240828","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: Examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Arch Osteoporos"},{"key":"R2-2-20240828","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: Medical management, epidemiology and economic burden.A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"R3-2-20240828","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00223-012-9666-6","article-title":"Assessing the impact of osteoporosis on the burden of hip fractures","volume":"92","author":"Od\u00e9n","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"R4-2-20240828","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrendo.2014.55","article-title":"Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW)","volume":"10","author":"Watts","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"R5-2-20240828","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"R6-2-20240828","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R7-2-20240828","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2009.1462","article-title":"Incidence and mortality of hip fractures in the United States","volume":"302","author":"Brauer","year":"2009","journal-title":"JAMA"},{"key":"R8-2-20240828","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: A compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch Osteoporos"},{"key":"R9-2-20240828","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.5650100202","article-title":"How many women have osteoporosis now?","volume":"10","author":"Melton","year":"1995","journal-title":"J Bone Miner Res"},{"key":"R10-2-20240828","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00198-004-1680-8","article-title":"Osteoporosis is markedly underdiagnosed: A nationwide study from Denmark","volume":"16","author":"Vestergaard","year":"2005","journal-title":"Osteoporos Int"},{"key":"R11-2-20240828","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI28550","article-title":"Estrogen deficiency and bone loss: An inflammatory tale","volume":"116","author":"Weitzmann","year":"2006","journal-title":"J Clin Invest"},{"key":"R12-2-20240828","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1038\/boneres.2016.41","article-title":"Vitamin D, calcium homeostasis and aging","volume":"4","author":"Veldurthy","year":"2016","journal-title":"Bone Res"},{"key":"R13-2-20240828","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrrheum.2012.93","article-title":"Recognizing and treating secondary osteoporosis","volume":"8","author":"Walker-Bone","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"R14-2-20240828","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: An update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"R15-2-20240828","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/acr.22346","article-title":"United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis","volume":"66","author":"Overman","year":"2014","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R16-2-20240828","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"R17-2-20240828","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.abb.2008.03.027","article-title":"Osteoclast-osteoblast communication","volume":"473","author":"Matsuo","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"R18-2-20240828","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1593","article-title":"Skeletal remodeling in health and disease","volume":"13","author":"Zaidi","year":"2007","journal-title":"Nat Med"},{"key":"R19-2-20240828","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0006-291X(89)92795-2","article-title":"Activation of the bone-derived latent TGF beta complex by isolated osteoclasts","volume":"158","author":"Oreffo","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"R20-2-20240828","doi-asserted-by":"crossref","first-page":"100207","DOI":"10.1016\/j.bonr.2019.100207","article-title":"Bone morphogenetic proteins: Their role in regulating osteoclast differentiation","volume":"10","author":"Huntley","year":"2019","journal-title":"Bone Rep"},{"key":"R21-2-20240828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/diagnostics10030145","article-title":"A review of the potential application of osteocyte-related biomarkers, fibroblast growth factor-23, sclerostin, and dickkopf-1 in predicting osteoporosis and fractures","volume":"10","author":"Ramli","year":"2020","journal-title":"Diagnostics (Basel"},{"key":"R22-2-20240828","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s00223-009-9303-1","article-title":"Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells","volume":"85","author":"Mak","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"R23-2-20240828","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bone.2009.03.673","article-title":"Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice","volume":"45","author":"Kalak","year":"2009","journal-title":"Bone"},{"key":"R24-2-20240828","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bone.2009.06.030","article-title":"Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity","volume":"46","author":"Weinstein","year":"2010","journal-title":"Bone"},{"key":"R25-2-20240828","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bone.2010.06.002","article-title":"Col3.6-HSD2 transgenic mice: A glucocorticoid loss-of-function model spanning early and late osteoblast differentiation","volume":"47","author":"Yang","year":"2010","journal-title":"Bone"},{"key":"R26-2-20240828","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/en.2003-0655","article-title":"Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone","volume":"145","author":"Sher","year":"2004","journal-title":"Endocrinology"},{"key":"R27-2-20240828","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","article-title":"Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor","volume":"11","author":"Rauch","year":"2010","journal-title":"Cell Metab"},{"key":"R28-2-20240828","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000314298","article-title":"Skeletal diseases in Cushing's syndrome: Osteoporosis versus arthropathy","volume":"92","author":"Kaltsas","year":"2010","journal-title":"Neuroendocrinology"},{"key":"R29-2-20240828","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3171\/2016.1.JNS152119","article-title":"Cushing's disease: Pathobiology, diagnosis, and management","volume":"126","author":"Lonser","year":"2017","journal-title":"J Neurosurg"},{"key":"R30-2-20240828","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00198-017-4241-7","article-title":"Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans","volume":"29","author":"Belaya","year":"2018","journal-title":"Osteoporos Int"},{"key":"R31-2-20240828","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2796.2011.02352.x","article-title":"Risk of hip fracture in Addison's disease: A population-based cohort study","volume":"270","author":"Bj\u00f6rnsdottir","year":"2011","journal-title":"J Intern Med"},{"key":"R32-2-20240828","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"key":"R33-2-20240828","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1242\/dev.01564","article-title":"Sequential roles of hedgehog and Wnt signaling in osteoblast development","volume":"132","author":"Hu","year":"2005","journal-title":"Development"},{"key":"R34-2-20240828","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.devcel.2005.02.013","article-title":"Canonical Wnt\/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes","volume":"8","author":"Hill","year":"2005","journal-title":"Dev Cell"},{"key":"R35-2-20240828","doi-asserted-by":"crossref","first-page":"24004","DOI":"10.1074\/jbc.M501080200","article-title":"Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms","volume":"280","author":"Kennell","year":"2005","journal-title":"J Biol Chem"},{"key":"R36-2-20240828","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7","article-title":"Inhibition of Osf2\/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2","volume":"74","author":"Lecka-Czernik","year":"1999","journal-title":"J Cell Biochem"},{"key":"R37-2-20240828","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1128\/MCB.16.8.4128","article-title":"Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C\/EBPbeta, C\/EBPdelta, and glucocorticoids","volume":"16","author":"Wu","year":"1996","journal-title":"Mol Cell Biol"},{"key":"R38-2-20240828","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/aps.2017.134","article-title":"Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15\/PPAR\u03b32 signaling in GIO rats","volume":"39","author":"Yang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"R39-2-20240828","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/jcb.22319","article-title":"BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts","volume":"108","author":"Zhang","year":"2009","journal-title":"J Cell Biochem"},{"key":"R40-2-20240828","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1359\/jbmr.2003.18.10.1842","article-title":"BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop","volume":"18","author":"Rawadi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"R41-2-20240828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bone.2012.09.029","article-title":"Wnt\/\u03b2-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts","volume":"52","author":"Zhang","year":"2013","journal-title":"Bone"},{"key":"R42-2-20240828","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000075025","article-title":"Identification of potential modifiers of Runx2\/Cbfa1 activity in C2C12 cells in response to bone morphogenetic protein-7","volume":"176","author":"Gu","year":"2004","journal-title":"Cells Tissues Organs"},{"key":"R43-2-20240828","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/jcb.22412","article-title":"The role of BMP-7 in chondrogenic and osteogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in vitro","volume":"109","author":"Shen","year":"2010","journal-title":"J Cell Biochem"},{"key":"R44-2-20240828","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1038\/s41598-018-26300-z","article-title":"Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo","volume":"8","author":"Hildebrandt","year":"2018","journal-title":"Sci Rep"},{"key":"R45-2-20240828","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbrc.2004.04.025","article-title":"Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: Novel mechanism of glucocorticoid-induced osteoporosis","volume":"318","author":"Ohnaka","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R46-2-20240828","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/art.23454","article-title":"Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice","volume":"58","author":"Yao","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R47-2-20240828","first-page":"970","article-title":"Polygonum multiflorm alleviates glucocorticoid-induced osteoporosis and Wnt signaling pathway","volume":"17","author":"Zhou","year":"2018","journal-title":"Mol Med Rep"},{"key":"R48-2-20240828","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","article-title":"Secreted antagonists of the Wnt signalling pathway","volume":"116","author":"Kawano","year":"2003","journal-title":"J Cell Sci"},{"key":"R49-2-20240828","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2008.12.035","article-title":"BMP\/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: Potential therapeutic targets for glucocorticoid-induced osteoporosis","volume":"379","author":"Hayashi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"R50-2-20240828","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1530\/EC-19-0104","article-title":"Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans","volume":"8","author":"Thiele","year":"2019","journal-title":"Endocr Connect"},{"key":"R51-2-20240828","doi-asserted-by":"crossref","first-page":"e10341","DOI":"10.1002\/jbm4.10341","article-title":"Short-term glucocorticoid treatment reduces circulating sclerostin concentrations in healthy young Men: A randomized, placebo-controlled, double-blind study","volume":"4","author":"Jacobsson","year":"2020","journal-title":"JBMR Plus"},{"key":"R52-2-20240828","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08977190802277880","article-title":"BMP-2 vs.BMP-4 expression and activity in glucocorticoid-arrested MC3T3-E1 osteoblasts: Smad signaling, not alkaline phosphatase activity, predicts rescue of mineralization","volume":"26","author":"Luppen","year":"2008","journal-title":"Growth Factors"},{"key":"R53-2-20240828","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S8756-3282(02)00687-7","article-title":"Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: Correlation with CCAAT-enhancer binding protein expression","volume":"30","author":"Pereira","year":"2002","journal-title":"Bone"},{"key":"R54-2-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jcb.24646","article-title":"Glucocorticoids antagonize RUNX2 during osteoblast differentiation in cultures of ST2 pluripotent mesenchymal cells","volume":"115","author":"Koromila","year":"2014","journal-title":"J Cell Biochem"},{"key":"R55-2-20240828","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1038\/sj.onc.1205937","article-title":"Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein","volume":"21","author":"Lee","year":"2002","journal-title":"Oncogene"},{"key":"R56-2-20240828","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1359\/JBMR.0301239","article-title":"Cooperation between TGF-beta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells","volume":"19","author":"Zhou","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R57-2-20240828","doi-asserted-by":"crossref","first-page":"31009","DOI":"10.1074\/jbc.273.47.31009","article-title":"Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17\/2.8 cells and primary rat calvaria cells","volume":"273","author":"Li","year":"1998","journal-title":"J Biol Chem"},{"key":"R58-2-20240828","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1093\/emboj\/20.9.2254","article-title":"TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation","volume":"20","author":"Alliston","year":"2001","journal-title":"EMBO J"},{"key":"R59-2-20240828","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/sj.emboj.7600729","article-title":"Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3","volume":"24","author":"Kang","year":"2005","journal-title":"EMBO J"},{"key":"R60-2-20240828","doi-asserted-by":"crossref","first-page":"9460","DOI":"10.1128\/MCB.25.21.9460-9468.2005","article-title":"Loss of Smad3-mediated negative regulation of Runx2 activity leads to an alteration in cell fate determination","volume":"25","author":"Hjelmeland","year":"2005","journal-title":"Mol Cell Biol"},{"key":"R61-2-20240828","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jcp.1041600214","article-title":"TGF beta alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype","volume":"160","author":"Breen","year":"1994","journal-title":"J Cell Physiol"},{"key":"R62-2-20240828","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1359\/jbmr.2001.16.10.1754","article-title":"The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis","volume":"16","author":"Borton","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R63-2-20240828","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nm.1979","article-title":"TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation","volume":"15","author":"Tang","year":"2009","journal-title":"Nat Med"},{"key":"R64-2-20240828","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.1038\/s41598-017-09793-y","article-title":"Transforming Growth Factor Beta is regulated by a Glucocorticoid-Dependent Mechanism in Denervation Mouse Bone","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"R65-2-20240828","doi-asserted-by":"crossref","first-page":"41342","DOI":"10.1074\/jbc.M502168200","article-title":"Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src\/ERK and phosphatidylinositol 3-kinase\/AKT","volume":"280","author":"Almeida","year":"2005","journal-title":"J Biol Chem"},{"key":"R66-2-20240828","doi-asserted-by":"crossref","first-page":"44061","DOI":"10.1074\/jbc.M207205200","article-title":"Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis","volume":"277","author":"Karsdal","year":"2002","journal-title":"J Biol Chem"},{"key":"R67-2-20240828","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1359\/jbmr.1998.13.5.793","article-title":"Osteoblast programmed cell death (apoptosis): Modulation by growth factors and cytokines","volume":"13","author":"Jilka","year":"1998","journal-title":"J Bone Miner Res"},{"key":"R68-2-20240828","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1359\/jbmr.1998.13.8.1243","article-title":"The role of estrogen in the control of rat osteocyte apoptosis","volume":"13","author":"Tomkinson","year":"1998","journal-title":"J Bone Miner Res"},{"key":"R69-2-20240828","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.physbeh.2009.04.025","article-title":"Estrogen regulation of apoptosis in osteoblasts","volume":"99","author":"Bradford","year":"2010","journal-title":"Physiol Behav"},{"key":"R70-2-20240828","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbamcr.2019.06.014","article-title":"Estrogen enhances human osteoblast survival and function via promotion of autophagy","volume":"1866","author":"Gavali","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"R71-2-20240828","first-page":"115","article-title":"Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"R72-2-20240828","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R73-2-20240828","doi-asserted-by":"crossref","first-page":"151422","DOI":"10.1016\/j.aanat.2019.151422","article-title":"The osteocyte: A multifunctional cell within the bone","volume":"227","author":"Tresguerres","year":"2020","journal-title":"Ann Anat"},{"key":"R74-2-20240828","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S8756-3282(96)00365-1","article-title":"Identification of apoptotic changes in osteocytes in normal and pathological human bone","volume":"20","author":"Noble","year":"1997","journal-title":"Bone"},{"key":"R75-2-20240828","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1359\/jbmr.2000.15.1.60","article-title":"Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo","volume":"15","author":"Verborgt","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R76-2-20240828","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bone.2011.09.052","article-title":"Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression","volume":"50","author":"Cheung","year":"2012","journal-title":"Bone"},{"key":"R77-2-20240828","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bone.2012.01.025","article-title":"Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations","volume":"50","author":"Kennedy","year":"2012","journal-title":"Bone"},{"key":"R78-2-20240828","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1096\/fj.11-182519","article-title":"Glucocorticoid dose determines osteocyte cell fate","volume":"25","author":"Jia","year":"2011","journal-title":"FASEB J"},{"key":"R79-2-20240828","doi-asserted-by":"crossref","first-page":"e37030","DOI":"10.1371\/journal.pone.0037030","article-title":"Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"R80-2-20240828","first-page":"4307","article-title":"Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Med Rep"},{"key":"R81-2-20240828","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","article-title":"Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength","volume":"145","author":"O'Brien","year":"2004","journal-title":"Endocrinology"},{"key":"R82-2-20240828","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1677\/joe.0.1560107","article-title":"Effects of cortisol on the expression of interleukin-6 and interleukin-1 beta in human osteoblast-like cells","volume":"156","author":"Swolin-Eide","year":"1998","journal-title":"J Endocrinol"},{"key":"R83-2-20240828","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"R84-2-20240828","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/0022034513500306","article-title":"Advances in the regulation of osteoclasts and osteoclast functions","volume":"92","author":"Boyce","year":"2013","journal-title":"J Dent Res"},{"key":"R85-2-20240828","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4068\/cmj.2016.52.1.12","article-title":"Signaling Pathways in Osteoclast Differentiation","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med J"},{"key":"R86-2-20240828","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","article-title":"The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development","volume":"103","author":"Fata","year":"2000","journal-title":"Cell"},{"key":"R87-2-20240828","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20051150","article-title":"Autoamplification of NFATc1 expression determines its essential role in bone homeostasis","volume":"202","author":"Asagiri","year":"2005","journal-title":"J Exp Med"},{"key":"R88-2-20240828","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1128\/MCB.20.18.6779-6798.2000","article-title":"Both src-dependent and -independent mechanisms mediate phosphatidylinositol 3-kinase regulation of colony-stimulating factor 1-activated mitogen-activated protein kinases in myeloid progenitors","volume":"20","author":"Lee","year":"2000","journal-title":"Mol Cell Biol"},{"key":"R89-2-20240828","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/endo.139.3.5778","article-title":"Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells","volume":"139","author":"Rubin","year":"1998","journal-title":"Endocrinology"},{"key":"R90-2-20240828","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","article-title":"M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase","volume":"10","author":"Glantschnig","year":"2003","journal-title":"Cell Death Differ"},{"key":"R91-2-20240828","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"key":"R92-2-20240828","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr Rev"},{"key":"R93-2-20240828","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat Med"},{"key":"R94-2-20240828","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R95-2-20240828","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/abbs\/gmq086","article-title":"Osteogenic growth peptide enhances the proliferation of bone marrow mesenchymal stem cells from osteoprotegerin-deficient mice by CDK2\/cyclin A","volume":"42","author":"Fei","year":"2010","journal-title":"Acta Biochim Biophys Sin (Shanghai"},{"key":"R96-2-20240828","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"R97-2-20240828","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0959-437X(00)00228-8","article-title":"Genetic control of skeletal development","volume":"11","author":"Wagner","year":"2001","journal-title":"Curr Opin Genet Dev"},{"key":"R98-2-20240828","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"R99-2-20240828","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.169.6.3353","article-title":"IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae","volume":"169","author":"Palmqvist","year":"2002","journal-title":"J Immunol"},{"key":"R100-2-20240828","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"R101-2-20240828","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1359\/JBMR.041233","article-title":"Influence of glucocorticoids on human osteoclast generation and activity","volume":"20","author":"Sivagurunathan","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R102-2-20240828","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell"},{"key":"R103-2-20240828","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1084\/jem.182.5.1461","article-title":"Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors","volume":"182","author":"Udagawa","year":"1995","journal-title":"J Exp Med"},{"key":"R105-2-20240828","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","article-title":"Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density","volume":"147","author":"Jia","year":"2006","journal-title":"Endocrinology"},{"key":"R106-2-20240828","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI0214538","article-title":"Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids","volume":"109","author":"Weinstein","year":"2002","journal-title":"J Clin Invest"},{"key":"R107-2-20240828","doi-asserted-by":"crossref","first-page":"e0142519","DOI":"10.1371\/journal.pone.0142519","article-title":"Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas\/Fas Ligand Pathway","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"R108-2-20240828","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1359\/JBMR.041022","article-title":"RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts","volume":"20","author":"Wu","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R109-2-20240828","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI28084","article-title":"Glucocorticoids suppress bone formation via the osteoclast","volume":"116","author":"Kim","year":"2006","journal-title":"J Clin Invest"},{"key":"R110-2-20240828","doi-asserted-by":"crossref","first-page":"421746","DOI":"10.1155\/2015\/421746","article-title":"Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells","volume":"2015","author":"Florencio-Silva","year":"2015","journal-title":"Biomed Res Int"},{"key":"R111-2-20240828","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: From human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"R112-2-20240828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdsr.2016.09.002","article-title":"Ultrastructural and biochemical aspects of matrix vesicle-mediated mineralization","volume":"53","author":"Hasegawa","year":"2017","journal-title":"Jpn Dent Sci Rev"},{"key":"R113-2-20240828","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0014-5793(86)80993-0","article-title":"Organization of hydroxyapatite crystals within collagen fibrils","volume":"206","author":"Weiner","year":"1986","journal-title":"FEBS Lett"},{"key":"R114-2-20240828","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-005-0017-7","article-title":"Mechanisms of glucocorticoid action in bone","volume":"3","author":"Canalis","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"R115-2-20240828","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcb.240570314","article-title":"Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms","volume":"57","author":"Delany","year":"1995","journal-title":"J Cell Biochem"},{"key":"R116-2-20240828","doi-asserted-by":"crossref","first-page":"26607","DOI":"10.1074\/jbc.270.44.26607","article-title":"Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms","volume":"270","author":"Delany","year":"1995","journal-title":"J Biol Chem"},{"key":"R117-2-20240828","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3389\/fphar.2020.00757","article-title":"The bone extracellular matrix in bone formation and regeneration","volume":"11","author":"Lin","year":"2020","journal-title":"Front Pharmacol"},{"key":"R118-2-20240828","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s004180050103","article-title":"Immunolocalization of tissue non-specific alkaline phosphatase in mice","volume":"107","author":"Hoshi","year":"1997","journal-title":"Histochem Cell Biol"},{"key":"R119-2-20240828","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/002215540205000305","article-title":"Histochemical localization of alkaline phosphatase activity in decalcified bone and cartilage","volume":"50","author":"Miao","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"R120-2-20240828","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1073\/pnas.142063399","article-title":"Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization","volume":"99","author":"Hessle","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R121-2-20240828","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2015.05.046","article-title":"New insights into the biology of osteocalcin","volume":"82","author":"Zoch","year":"2016","journal-title":"Bone"},{"key":"R122-2-20240828","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1002\/jcb.27948","article-title":"Synergistic effect of extracellularly supplemented osteopontin and osteocalcin on stem cell proliferation, osteogenic differentiation, and angiogenic properties","volume":"120","author":"Carvalho","year":"2019","journal-title":"J Cell Biochem"},{"key":"R123-2-20240828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0092-8674(81)90037-4","article-title":"Osteonectin, a bone-specific protein linking mineral to collagen","volume":"26","author":"Termine","year":"1981","journal-title":"Cell"},{"key":"R124-2-20240828","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1172\/JCI7039C1","article-title":"Osteopenia and decreased bone formation in osteonectin-deficient mice","volume":"105","author":"Delany","year":"2000","journal-title":"J Clin Invest"},{"key":"R125-2-20240828","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bone.2004.06.019","article-title":"A scrutiny of matrix metalloproteinases in osteoclasts: Evidence for heterogeneity and for the presence of MMPs synthesized by other cells","volume":"35","author":"Andersen","year":"2004","journal-title":"Bone"},{"key":"R126-2-20240828","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","article-title":"Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts","volume":"271","author":"Drake","year":"1996","journal-title":"J Biol Chem"},{"key":"R127-2-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.matbio.2018.01.024","article-title":"Cysteine cathepsins in extracellular matrix remodeling: Extracellular matrix degradation and beyond","volume":"75-76","author":"Vizovi\u0161ek","year":"2019","journal-title":"Matrix Biol"},{"key":"R128-2-20240828","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00774-005-0627-2","article-title":"Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells","volume":"23","author":"Iu","year":"2005","journal-title":"J Bone Miner Metab"},{"key":"R129-2-20240828","first-page":"3379","article-title":"The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: A potential mechanism for negative regulation","volume":"11","author":"Str\u00f6mstedt","year":"1991","journal-title":"Mol Cell Biol"},{"key":"R130-2-20240828","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/0006-291X(92)92336-V","article-title":"The effect of active vitamin D3 analogs and dexamethasone on the expression of osteocalcin gene in rat tibiae in vivo","volume":"189","author":"Ikeda","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"R131-2-20240828","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/jbmr.5650080810","article-title":"Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter","volume":"8","author":"Morrison","year":"1993","journal-title":"J Bone Miner Res"},{"key":"R132-2-20240828","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.biopha.2018.02.082","article-title":"Possible mechanisms of prednisolone-induced osteoporosis in zebrafish larva","volume":"101","author":"He","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R133-2-20240828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.clpt.6100450","article-title":"Cathepsin K inhibitors: A novel target for osteoporosis therapy","volume":"83","author":"Stoch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R134-2-20240828","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int"},{"key":"R135-2-20240828","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the adjustment of FRAX according to the dose of glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"R137-2-20240828","doi-asserted-by":"crossref","first-page":"e5959","DOI":"10.1097\/MD.0000000000005959","article-title":"Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey","volume":"96","author":"Yu","year":"2017","journal-title":"Medicine (Baltimore"},{"key":"R138-2-20240828","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00774-019-01046-4","article-title":"Novel algorithm generating strategy to identify high fracture risk population using a hybrid intervention threshold","volume":"38","author":"Hsu","year":"2020","journal-title":"J Bone Miner Metab"},{"key":"R139-2-20240828","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R140-2-20240828","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrrheum.2014.188","article-title":"Glucocorticoid-induced osteoporosis: Who to treat with what agent?","volume":"11","author":"Rizzoli","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"R141-2-20240828","doi-asserted-by":"crossref","first-page":"G92","DOI":"10.1152\/ajpgi.00317.2006","article-title":"Prednisolone-induced Ca2+malabsorption is caused by diminished expression of the epithelial Ca2+channel TRPV6","volume":"292","author":"Huybers","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R142-2-20240828","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000180820","article-title":"Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics","volume":"27","author":"Reid","year":"1987","journal-title":"Horm Res"},{"key":"R143-2-20240828","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"R144-2-20240828","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R145-2-20240828","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"R146-2-20240828","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(99)00197-0","article-title":"Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment","volume":"25","author":"Ito","year":"1999","journal-title":"Bone"},{"key":"R147-2-20240828","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"R148-2-20240828","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMct1004903","article-title":"Bisphosphonates for osteoporosis","volume":"363","author":"Favus","year":"2010","journal-title":"N Engl J Med"},{"key":"R149-2-20240828","first-page":"175","article-title":"Intravenous bisphosphonates for postmenopausal osteoporosis","volume":"15","author":"Mottaghi","year":"2010","journal-title":"J Res Med Sci"},{"key":"R150-2-20240828","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N Engl J Med"},{"key":"R151-2-20240828","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/clpt.2011.268","article-title":"Denosumab for the treatment of osteoporosis and cancer-related conditions","volume":"91","author":"Lewiecki","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R152-2-20240828","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R153-2-20240828","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.39075","article-title":"Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R154-2-20240828","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"},{"key":"R155-2-20240828","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral Fractures After Discontinuation of Denosumab: A Post hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R156-2-20240828","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2014.04.002","article-title":"Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period","volume":"64","author":"Boyce","year":"2014","journal-title":"Bone"},{"key":"R157-2-20240828","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fendo.2018.00162","article-title":"Osteoporosis Therapy With Denosumab in Organ Transplant Recipients","volume":"9","author":"Brunova","year":"2018","journal-title":"Front Endocrinol (Lausanne"},{"key":"R158-2-20240828","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1159\/000503066","article-title":"Follow-p of bone mineral density changes in de novo kidney transplant recipients treated with two doses of the receprtor activator of nuclear factor kappaB ligand inhibitor denosumab","volume":"44","author":"Kobel","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"R159-2-20240828","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis.Results of a randomized controlled clinical trial","volume":"102","author":"Lane","year":"1998","journal-title":"J Clin Invest"},{"key":"R160-2-20240828","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"R161-2-20240828","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.bonr.2020.100293","article-title":"Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment","volume":"13","author":"Hirooka","year":"2020","journal-title":"Bone Rep"},{"key":"R162-2-20240828","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/8756-3282(94)90322-0","article-title":"Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow","volume":"15","author":"Nishida","year":"1994","journal-title":"Bone"},{"key":"R163-2-20240828","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"R164-2-20240828","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"R165-2-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation","volume":"11","author":"Guo","year":"2010","journal-title":"Cell Metab"},{"key":"R166-2-20240828","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest"},{"key":"R167-2-20240828","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1210\/en.2009-1488","article-title":"Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice","volume":"151","author":"Weinstein","year":"2010","journal-title":"Endocrinology"},{"key":"R168-2-20240828","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1101\/gad.1702708","article-title":"Parathyroid hormone signaling through low-density lipoprotein-related protein 6","volume":"22","author":"Wan","year":"2008","journal-title":"Genes Dev"},{"key":"R169-2-20240828","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures","volume":"83","author":"Canalis","year":"1989","journal-title":"J Clin Invest"},{"key":"R170-2-20240828","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1359\/jbmr.070517","article-title":"IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone","volume":"22","author":"Wang","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R171-2-20240828","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcb.10490","article-title":"Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone","volume":"89","author":"Locklin","year":"2003","journal-title":"J Cell Biochem"},{"key":"R172-2-20240828","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1359\/JBMR.0301226","article-title":"PTH differentially regulates expression of RANKL and OPG","volume":"19","author":"Huang","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R173-2-20240828","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial","volume":"28","author":"Gl\u00fcer","year":"2013","journal-title":"J Bone Miner Res"},{"key":"R174-2-20240828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/0253-7613.93869","article-title":"Severe hypercalcemia due to teriparatide","volume":"44","author":"Karatoprak","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"R176-2-20240828","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MAJ.0b013e31820865d5","article-title":"Differentiation of human mesenchymal stem cells: The potential mechanism for estrogen-induced preferential osteoblast versus adipocyte differentiation","volume":"341","author":"Zhao","year":"2011","journal-title":"Am J Med Sci"},{"key":"R177-2-20240828","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S8756-3282(01)00685-8","article-title":"The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro","volume":"30","author":"Taranta","year":"2002","journal-title":"Bone"},{"key":"R178-2-20240828","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1210\/jc.2013-3249","article-title":"Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women","volume":"99","author":"Fujita","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R179-2-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jbmr.128","article-title":"Regulation of circulating sclerostin levels by sex steroids in women and in men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R180-2-20240828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mce.2016.11.005","article-title":"Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice","volume":"440","author":"Kalam","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"R181-2-20240828","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00198-007-0452-7","article-title":"Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: A pilot study","volume":"19","author":"Taxel","year":"2008","journal-title":"Osteoporos Int"},{"key":"R182-2-20240828","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/endo.142.6.8220","article-title":"17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha","volume":"142","author":"Saika","year":"2001","journal-title":"Endocrinology"},{"key":"R183-2-20240828","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.intimp.2016.08.014","article-title":"Daidzein increases OPG\/RANKL ratio and suppresses IL-6 in MG-63 osteoblast cells","volume":"40","author":"Sun","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"R184-2-20240828","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nm1096-1132","article-title":"Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta","volume":"2","author":"Hughes","year":"1996","journal-title":"Nat Med"},{"key":"R185-2-20240828","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.bjp.0707232","article-title":"Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro","volume":"151","author":"Michael","year":"2007","journal-title":"Br J Pharmacol"},{"key":"R186-2-20240828","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00223-007-9050-0","article-title":"Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women","volume":"81","author":"van Essen","year":"2007","journal-title":"Calcif Tissue Int"},{"key":"R187-2-20240828","first-page":"57","article-title":"The problems of developing a healthy life style and the treatment and rehabilitation of the population of the USSR from the viewpoints of the Ayurvedic approaches of the Maharishi","volume":"1","author":"Polunin","year":"1992","journal-title":"Vopr Kurortol Fizioter Lech Fiz Kult"},{"key":"R188-2-20240828","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial.Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"R189-2-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/gme.0b013e3181e84bb4","article-title":"Postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial: 5-year gynecological outcomes","volume":"18","author":"Goldstein","year":"2011","journal-title":"Menopause"},{"key":"R190-2-20240828","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00198-013-2341-6","article-title":"An evaluation of the Fracture Risk Assessment Tool (FRAX\u00ae) as an indicator of treatment efficacy: The effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX\u00ae","volume":"24","author":"Kaufman","year":"2013","journal-title":"Osteoporos Int"},{"key":"R191-2-20240828","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"R192-2-20240828","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00508-016-1019-4","article-title":"Diagnosis and management of asthma-Statement on the 2015 GINA Guidelines","volume":"128","author":"Horak","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"R193-2-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11914-014-0228-x","article-title":"Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: Epidemiology, mechanisms, diagnosis, and treatment","volume":"12","author":"von Scheven","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"R194-2-20240828","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1359\/jbmr.2003.18.5.913","article-title":"Children and the risk of fractures caused by oral corticosteroids","volume":"18","author":"van Staa","year":"2003","journal-title":"J Bone Miner Res"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_233_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:24:03Z","timestamp":1787844243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_233_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":191,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_233_20","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}